Gilead (GILD) Reiterates Confidence on Hitting PFS Improvement in HR+/HER2- Trial - BMO Capital Markets
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $85.00 price target on Gilead Sciences (NASDAQ: GILD) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
